Tacrolimus effect on rosacea - 24/08/11
Doi : 10.1016/S0190-9622(03)02157-1
Joel T.M Bamford, MD ⁎, a 
, Barbara A Elliott, PhD b, Irina V Haller, PhD, MS c
, Barbara A Elliott, PhD b, Irina V Haller, PhD, MS c a Dermatology Section, St. Mary's/Duluth Clinic Health System, USA
b School of Medicine Duluth, University of Minnesota,, USA
c Division of Education and Research, St. Mary's/Duluth Clinic Health System., USA
*Correspondence to: Joel T.M. Bamford, MD, Dermatologist St Mary's/Duluth Clinic Health System 400 E Third St, Duluth, MN 55805, USA.
Abstract |
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P < .05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.
Il testo completo di questo articolo è disponibile in PDF.Mappa
 | Conflict of interest: None identified. |
© 2004
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 50 - N° 1
P. 107-108 - gennaio 2004 Ritorno al numero
Articolo precedente
- Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis
- Jan R Mekkes, Miriam A Loots, Allard C van der Wal, Jan D Bos
- UV light–induced linear IgA dermatosis
- Wolfgang Salmhofer, H.Peter Soyer, Peter Wolf, Dagmar Födinger, Stefan Hödl, Helmut Kerl
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?